High resolution far-infrared Fourier transform spectroscopy of radicals at the AILES beamline of SOLEIL synchrotron facility.

Experimental far-infrared (FIR) spectroscopy of transient species (unstable molecules, free radicals, and ions) has been limited so far in both emission and absorption (mainly by the low probability of spontaneous emission in that spectral range and the low brightness of continuum sources used for absorption measurements, respectively). Nevertheless, the FIR spectral range recently became of high astrophysical relevance thanks to several new observational platforms (HERSCHEL, ALMA...) dedicated to the study of this region suitable for the detection of the emission from cold objects of the interstellar medium. In order to complete the experimental dataset concerning transient species, three discharge experiments dedicated to the recording of high resolution FIR spectra of radicals have been developed at the Advanced Infrared Line Exploited for Spectroscopy (AILES) which extracts the bright FIR synchrotron continuum of the synchrotron facility SOLEIL. These experiments make use of a high resolution (R = 0.001 cm(-1)) Bruker IFS125 Fourier transform (FT) spectrometer. An emission setup (allowing to record spectra of radicals excited at high rotational and vibrational temperatures) and two absorption setups (exploiting the bright synchrotron source at the highest resolution available on the FT) are alternatively connected to the FT. The advantages and limitations of these techniques are discussed on the basis of the recent results obtained on OH and CH radicals. These results constitute the first FIR spectra of radicals using synchrotron radiation, and the first FIR spectrum of a C-bearing radical using FT-spectroscopy.

Extramedullary relapse after favorable molecular response to donor leukocyte infusions for recurring acute leukemia.

Donor leukocyte infusions (DLI) have turned out to be an efficient way to re-establish complete remission (CR) in chronic myeloid leukemia (CML) patients relapsing after allogeneic bone marrow transplantation (BMT). In these patients, absence of PCR bcr-abl fusion transcripts confirmed the potency of donor leukocytes to induce molecular response in relapsed CML. This ensured sustained remission and long-term survival. In this study, the capacity of DLI to induce molecular remission in acute leukemia relapse after BMT was analyzed. The results showed that following DLI, leukemic cell eradication gradually occurred over a prolonged time period. The time to complete disappearance of the molecular marker of the disease was 30 weeks in RT-PCR analysis. A sustained and persistent elimination of an AML1/ETO-positive leukemic clone in an AML-M2 patient was observed. In contrast, an AML-M5 with t(11;19) and an E2A/PBX1-positive ALL achieving cytogenetic and molecular bone marrow CR developed following DLI unusual sites of extramedullary leukemia relapse, despite continued bone marrow remission. This study adds further proof of the benefit of donor cell therapy in acute leukemia but shows that complete leukemic cell eradication appears to require a critical interval in order to establish effective immune responses at all sites where leukemic cells persist.